abma

ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens, efficiently protecting cells against various pathogens including viruses, intracellular bacteria, and parasites. ABMA selectively acts on host cell late endosomes rather than targeting the toxin or pathogen itself.

Anatumomab mafenatox (ABR-214936), a 73 KDa recombinant protein, targets the tumor-associated antigen 5T4 commonly expressed in malignancies. It is a conjugate comprising a modified form of SEA linked to a murine Fab. The primary adverse effects of Anatumomab mafenatox include fever, hypotension, pain, nausea, and drowsiness [1].

Vorsetuzumab mafodotin, a humanized anti-CD70 monoclonal antibody, conjugates with monomethyl auristatin F (MMAF) through Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. This affinity allows targeting of various solid tumors and cancers such as renal cell carcinoma, pancreatic, ovarian, and lung cancers, alongside multiple myeloma and several forms of non-Hodgkin lymphoma, all of which express CD70.